PRTN3 and rheumatoid arthritis: In addition to its known effects as a TLR4 agonist (20), the C-terminal fibrinogen-like domain of TNC has been shown to be citrullinated within synovial fluid (21), and immunodominant peptides within this domain are recognized by serum ACPA from subjects with RA (22).